-
公开(公告)号：US20240287191A1
公开(公告)日：2024-08-29
申请号：US18012600
申请日：2021-06-25
发明人： Hyea Kyung AHN , Young Ju KIM , Mi Jin JUNG
CPC分类号： C07K16/283 , A61K39/39591 , A61K47/183 , A61K47/20 , A61K47/22 , A61K47/26 , C07K2317/76
摘要： In one aspect of the present invention, there is provided a pharmaceutical formulation having a pH of 4.0 to 8.0, comprising (a) an HL161BKN antibody or a fragment thereof, (b) at least one additive selected from mannitol, sorbitol, arginine, histidine, glycine and salts thereof, (c) a buffer system selected from citrate or histidine, and (d) a surfactant. HL161BKN present in the formulation has improved stability and is non-toxic, and thus has a high potential for industrial application.
-
公开(公告)号：US20240059767A1
公开(公告)日：2024-02-22
申请号：US18261368
申请日：2021-01-14
发明人： Seung Kook Park , Hyea Kyung Ahn , Hye Eun Shim , Young Ju Kim , Sun Mi Park , Joo Hyun Chae
CPC分类号： C07K16/241 , A61K9/0048 , A61K47/12 , A61P27/02 , A61K2039/505
摘要： The present invention relates to treatment of dry eye syndrome using a tanfanercept-containing ophthalmic composition. According to the present invention, as a result of clinical trial on dry eye syndrome, the tanfanercept-containing ophthalmic composition demonstrated excellent effects with regard to improvement of a central corneal staining score (CCSS) and a total corneal staining score (TCSS), which is clinically important. Further, such improvement of a central corneal staining score (CCSS) and a total corneal staining score (TCSS) was more significantly demonstrated in the patients with moderate-to-severe severity of dry eye. In addition, the patients with higher ocular discomfort score or higher eye dryness score, which are subjective symptoms, also showed greater improvement. Even though the same dose of tanfanercept was used, the tanfanercept-containing ophthalmic composition showed superior efficacy in the patient having more serious or severe baseline sign or symptom scores. This result was unexpected and is meaningful under the existing conditions without therapeutics for moderate or severe dry eye syndrome, since a novel and alternative therapeutic idea may be provided.
-
公开(公告)号：US20230235063A1
公开(公告)日：2023-07-27
申请号：US18171967
申请日：2023-02-21
发明人： Sung Wuk Kim , Seung Kook Park , Jae Kap Jeong , Hyea Kyung Ahn , Min Sun Kim , Eun Sun Kim , Hae-Young Yong , Dongok Shin , Yeon Jung Song , Tae Hyoung Yoo
IPC分类号： C07K16/28 , G01N33/566 , G01N33/68 , G01N33/564
CPC分类号： C07K16/283 , G01N33/566 , G01N33/6854 , G01N33/564 , A61K2039/505
摘要： The present disclosure relates to an isolated anti-FcRN antibody, which is an antibody binding to FcRN (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
-
公开(公告)号：US10544226B2
公开(公告)日：2020-01-28
申请号：US15301948
申请日：2015-04-30
发明人： Sung Wuk Kim , Seung Kook Park , Jae Kap Jeong , Hyea Kyung Ahn , Min Sun Kim , Eun Sun Kim , Hae-Young Yong , Dongok Shin , Yeon Jung Song , Tae Hyoung Yoo
IPC分类号： C07K16/00 , C12P21/08 , C07H21/02 , C07H21/04 , C12P21/06 , C12P21/04 , C12N5/02 , C12N5/16 , C12N1/20 , A61K39/395 , A61K39/40 , C07K16/28 , G01N33/566 , G01N33/68 , G01N33/564 , A61K39/00
摘要： The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
-
5.发明授权公开(公告)号：US09655916B2
公开(公告)日：2017-05-23
申请号：US14600253
申请日：2015-01-20
发明人： Byung Cheol Shin , Hasoo Seong , Aeri Lee , Jae Yang Kong , Hyae Gyeong Cheon , Young Sik Cho , Sung Soo Jun , Young Gwan Jo
IPC分类号： A61K31/714 , A61K9/127 , A61K9/00 , A61K45/06 , A61K31/575 , A61K31/683 , A61K9/06 , A61K9/70
CPC分类号： A61K31/714 , A61K9/0014 , A61K9/06 , A61K9/127 , A61K9/7053 , A61K31/575 , A61K31/683 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). The composition contains adenosylcobalamin (coenzyme B12), optionally in admixture with other cobalamins. The composition can be present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.
-
6.发明申请COMPOSITIONS FOR EXTERNAL APPLICATION, CONTAINING ADENOSYLCOBALAMIN FOR IMPROVEMENT OF SKIN DISEASES 审中-公开用于外部应用的组合物，含有腺苷酸对改善皮肤病的作用公开(公告)号：US20150196581A1
公开(公告)日：2015-07-16
申请号：US14600253
申请日：2015-01-20
发明人： Byung Cheol SHIN , Hasoo SEONG , Aeri LEE , Jae Yang KONG , Hyae Gyeong CHEON , Young Sik CHO , Sung Soo JUN , Young Gwan JO
IPC分类号： A61K31/714 , A61K45/06 , A61K9/127
CPC分类号： A61K31/714 , A61K9/0014 , A61K9/06 , A61K9/127 , A61K9/7053 , A61K31/575 , A61K31/683 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a composition for external application for improving a skin disease (e.g. psoriasis). The composition contains adenosylcobalamin (coenzyme B12), optionally in admixture with other cobalamins. The composition can be present in the form of liposomal preparations, which are made of a phospholipid and cholesterol.
摘要翻译： 本发明涉及用于改善皮肤病（例如牛皮癣）的外用组合物。 该组合物含有腺苷钴胺素（辅酶B12），任选与其它钴胺素混合。 组合物可以以由磷脂和胆固醇制成的脂质体制剂的形式存在。
-
公开(公告)号：US20150126518A1
公开(公告)日：2015-05-07
申请号：US14528468
申请日：2014-10-30
发明人： Hong Woo KIM , Ji Sun LEE , Hye Jin HEO , Hong Bum LEE , Jae Kap JEONG , Ji Hyun PARK , Seo-il KIM , Young Woo LEE
IPC分类号： C07D495/04 , C07D241/04 , C07D211/60 , C07D401/12 , C07D405/12 , C07D207/16
CPC分类号： C07D495/04 , C07D207/16 , C07D211/60 , C07D241/04 , C07D401/12 , C07D405/12
摘要： The present invention relates to biguanide compounds and use thereof, more particularly, to biguanide derivatives exhibiting excellent effects for inhibition of cancer cell proliferation and inhibition of cancer metastasis and recurrence, a method for preparing the same, a pharmaceutical composition containing the same as an active ingredient, and a method of prevention or treatment of cancer comprising the step of administering an effective amount of the composition to a subject in need thereof.
摘要翻译： 本发明涉及双胍化合物及其用途，更具体地说，涉及对抑制癌细胞增殖和抑制癌症转移及复发具有优异效果的双胍衍生物及其制备方法，含有该活性成分的药物组合物 成分和预防或治疗癌症的方法，包括向有需要的受试者施用有效量的组合物的步骤。
-
公开(公告)号：US08114839B2
公开(公告)日：2012-02-14
申请号：US12157150
申请日：2008-06-06
申请人： Rene Gantier , Manuel Vega , Lila Drittanti , Thierry Guyon
发明人： Rene Gantier , Manuel Vega , Lila Drittanti , Thierry Guyon
CPC分类号： C07K14/475 , A61K38/00 , C07K14/505 , C07K14/52 , C07K14/53 , C07K14/535 , C07K14/54 , C07K14/555 , C07K14/575 , C07K14/61
摘要： Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.
摘要翻译： 提供了包括突变R131Q的修饰促红细胞生成素多肽及其用途。 还提供了药物组合物，包括配制用于口服给药的组合物，其含有修饰的促红细胞生成素多肽和该组合物用于治疗由促红细胞生成素治疗的疾病和病症的用途。
-
公开(公告)号：US20230391876A1
公开(公告)日：2023-12-07
申请号：US18340722
申请日：2023-06-23
发明人： William Louis MACIAS , Su LIANG , Hyeakyung AHN , Haeyoung YONG , Mijin JUNG , Minho YOON , Eunsun KIM , Seungkook PARK , Hyeeun SHIM
CPC分类号： C07K16/283 , A61P37/06 , A61K2039/505
摘要： The present disclosure relates to an anti-FcRn antibody or an antigen binding fragment thereof with improved stability and uses thereof. The anti-FcRn antibody or antigen binding fragment thereof binds to FcRn non-competitively with IgG and the like compared to the parent antibody, HL161AN, thereby having improved stability, such as reducing the production rate of aggregates while maintaining the biological activity of significantly reducing the amount of pathogenic autoantibodies in the blood. Therefore, it may be utilized more efficiently for the treatment of an autoimmune disease.
-
公开(公告)号：US10336825B2
公开(公告)日：2019-07-02
申请号：US15480264
申请日：2017-04-05
发明人： Sung Wuk Kim , Seung Kook Park , Jae Kap Jeong , Hyea Kyung Ahn , Min Sun Kim , Eun Sun Kim , Hae-Young Yong , Dongok Shin , Yeon Jung Song , Tae Hyoung Yoo
摘要： The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
-
-
-
-
-
-
-
-
-
搜索结果
62 条记录 (耗时 0.027 秒)
